MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
Log in

NASDAQ:NBIXNeurocrine Biosciences Stock Price, Forecast & News

$128.76
+1.10 (+0.86 %)
(As of 07/7/2020 12:44 PM ET)
Add
Compare
Today's Range
$126.15
Now: $128.76
$130.00
50-Day Range
$113.16
MA: $122.54
$130.36
52-Week Range
$72.14
Now: $128.76
$131.00
Volume8,210 shs
Average Volume864,364 shs
Market Capitalization$11.96 billion
P/E Ratio69.98
Dividend YieldN/A
Beta1.34
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL - Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Read More
Neurocrine Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$788.10 million
Cash Flow$0.70 per share
Book Value$6.92 per share

Profitability

Net Income$37.01 million

Miscellaneous

Employees585
Market Cap$11.96 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

How has Neurocrine Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NBIX shares have increased by 50.1% and is now trading at $128.96. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neurocrine Biosciences?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neurocrine Biosciences.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Neurocrine Biosciences.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Wednesday, May, 6th. The company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $237.10 million for the quarter, compared to analyst estimates of $226.29 million. Neurocrine Biosciences had a net margin of 19.90% and a return on equity of 37.53%. The business's quarterly revenue was up 71.3% on a year-over-year basis. During the same quarter last year, the company earned $0.29 EPS. View Neurocrine Biosciences' earnings history.

What price target have analysts set for NBIX?

18 brokers have issued 1 year target prices for Neurocrine Biosciences' stock. Their forecasts range from $100.00 to $153.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $127.76 in the next twelve months. This suggests that the stock has a possible downside of 0.9%. View analysts' price targets for Neurocrine Biosciences.

Has Neurocrine Biosciences been receiving favorable news coverage?

News headlines about NBIX stock have trended negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neurocrine Biosciences earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Neurocrine Biosciences.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), Trade Desk (TTD), salesforce.com (CRM) and Walt Disney (DIS).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View institutional ownership trends for Neurocrine Biosciences.

Which institutional investors are buying Neurocrine Biosciences stock?

NBIX stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Nelson Van Denburg & Campbell Wealth Management Group LLC. View insider buying and selling activity for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $128.96.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $11.98 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.